Prognostic value of neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte ratios and Glasgow prognostic score in osteosarcoma: A meta-analysis

Table 1 Basic characteristics of included studies

Ref.	Year	Country	Sample size	Indicators	Thresholds	Endpoints	NOS
Liu et al[16]	2015	China	327	LMR	3.43	OS, EFS	7
Aggerholm-Pedersen et al[18]	2016	Denmark	172	NLR, GPS	5.3	OS, CSS	7
Liu et al[17]	2016	China	162	NLR, PLR, LMR, GPS	2.57, 123.5, 4.73	OS	6
Xia et al[19]	2016	China	359	NLR, PLR	3.43, 122	OS, PFS	7
Li et al[20]	2017	China	216	NLR, PLR, GPS	2.65, 118	OS	6
Vasquez et al[21]	2017	Peru	55	NLR, PLR	2, 150	OS	6
Huang et al[22]	2018	China	103	NLR, mGPS	2.70	OS, EFS	7
Huang et al[23]	2019	China	126	NLR, PLR	2.1, 163.2	OS	7
Xu et al[24]	2019	China	150	NLR, PLR, LMR	2.7, 200, 3.0	OS, DFS	6
Hu et al[25]	2020	China	137	LMR	3.05	OS	7
Yang et al[26]	2020	China	133	NLR, LMR	2.96, 4.44	OS, PFS	6
Yang et al[27]	2020	China	77	NLR, PLR, LMR	2.65, 125.0, 5.16	OS	7
Ye et al[28]	2021	China	70	NLR, PLR, LMR	3.025, 111.5, 4.82	OS	7

NLR: Neutrophil/lymphocyte ratio; PLR: Platelet/lymphocyte ratio; LMR: Lymphocyte/monocyte ratio; GPS: Glasgow prognostic score; mGPS: Modified Glasgow prognostic score; OS: Overall survival; CSS: Cancer-specific survival; EFS: Event-free survival; DFS: Disease-free survival; NOS: Newcastle-Ottawa quality assessment scale.

Table 2 Results of meta-analysis

	No. of studies	HR	95%CI	P value	I2(%)	P value
Neutrophil/lymphocyte ratio
Overall survival	11	1.88	1.38-2.55	< 0.001	80.2	< 0.001
Disease-free survival	5	1.67	1.37-2.04	< 0.001	35.4	0.186
Platelet/lymphocyte ratio
Overall survival	7	1.29	0.97-1.72	0.085	77.4	< 0.000
Disease-free survival	2	1.12	0.87-1.44	0.396	0.0	0.465
Lymphocyte/monocyte ratio
Overall survival	6	0.82	0.54-1.23	0.338	70.8	0.004
Disease-free survival	2	0.68	0.41-1.11	0.124	76.1	0.041
Glasgow prognostic score
Overall survival	4	2.19	1.64-2.94	< 0.001	0.0	0.602
Disease-free survival	2	2.50	1.39-4.48	< 0.001	0.0	0.342

HR: Hazard ratio; CI: Confidence interval.